Background
Before recombinant technology, GH was extracted from cadaveric human pituitaries. This practice was discontinued in the 1980s after cases of iatrogenic Creutzfeldt–Jakob disease were linked to contaminated preparations. Recombinant somatropin became available in 1985 and replaced pituitary-derived GH, eliminating the prion transmission risk and enabling a more reliable supply. Genotropin, a Pharmacia/Pfizer formulation, gained regulatory approval for pediatric GH deficiency and later for adult GH deficiency and additional pediatric indications. Long-term registries — including the Pfizer International Growth Study (KIGS) and the Hypopituitary Control and Complications Study (HypoCCS) — have provided ongoing safety and efficacy data that continue to inform prescribing guidelines.
Evidence snapshot
Randomized and open-label trials in children with growth hormone deficiency demonstrate increased growth velocity and improved adult height when therapy is started early and dosed appropriately by weight and indication. Outcomes vary with age at initiation, dose, and underlying diagnosis.
In adults with confirmed growth hormone deficiency, somatropin replacement improves body composition (reduced fat mass, increased lean mass), bone turnover markers, and quality-of-life scores when doses are titrated to age-adjusted IGF-1 targets and adverse effects are monitored. Evidence does not support use for performance enhancement, anti-aging, or routine supplementation in healthy older adults, and such use carries meaningful risk.
Long-term safety is tracked through registries and regulatory pharmacovigilance. Clinically important adverse effects include fluid retention, glucose intolerance, and rare intracranial hypertension. GH is contraindicated in active malignancy; theoretical IGF-1-driven proliferative risk is monitored on a case-by-case basis in cancer survivors.
Bioavailability and administration
Somatropin is a 191-amino-acid protein that is degraded in the gastrointestinal tract and has no meaningful oral bioavailability. Subcutaneous injection is the standard route. Absorption from subcutaneous tissue is reliable, with peak serum concentrations typically reached within 3–5 hours of injection. Genotropin is supplied as a lyophilized powder for reconstitution or as a prefilled pen device. Injection timing is conventionally in the evening to align with physiologic nocturnal GH secretion peaks, though timing may be individualized. Injection sites should be rotated to minimize lipodystrophy.
Approved populations and indications
Regulatory approvals (FDA, EMA) cover pediatric GH deficiency, Turner syndrome, children born small for gestational age who fail to demonstrate catch-up growth, Prader-Willi syndrome, idiopathic short stature (in selected jurisdictions), and adult GH deficiency. Registry and trial evidence supports increased growth velocity in pediatric populations and improvements in body composition and quality of life in adults with biochemically confirmed deficiency. Off-label uses — including athletic performance enhancement and anti-aging — are not supported by clinical evidence and are discouraged due to safety risks.
Long-term safety and monitoring
Short-term adverse effects (fluid retention, arthralgia, glucose intolerance) are generally dose-dependent and manageable. Routine monitoring includes IGF-1, fasting glucose/HbA1c, lipid panel, thyroid function, and clinical assessment for edema or intracranial hypertension at each follow-up visit. Concerns about cancer risk stem from IGF-1's role in cell proliferation; current evidence from registries does not demonstrate a clear increased incidence of de-novo malignancy in patients treated for approved indications, but GH is contraindicated in active malignancy and requires individualized risk-benefit assessment in cancer survivors. Long-term registry programs continue to monitor rare outcomes.
Practical prescribing considerations
Pediatric dosing is weight-based and given daily; adult replacement uses lower fixed starting doses titrated to IGF-1 response. Insurance coverage typically requires documented deficiency (provocative GH testing in adults, auxological criteria in children) and ongoing monitoring records. Because GH raises fasting glucose, patients with diabetes or pre-diabetes need closer follow-up and may require adjustment of antidiabetic medications. Thyroid function should be evaluated before and during therapy, as GH can unmask central hypothyroidism.
Compound variations
Genotropin (vial for reconstitution)
Lyophilized somatropin reconstituted with provided diluent and administered by syringe.
Common use case
Clinical settings or patients who prefer vial-based dosing and syringe administration.
Dosage note
Prepare and store per manufacturer label; dose drawn with syringe according to prescription.
Genotropin GoQuick Pen (prefilled pen)
Prefilled, multidose injection pen with dose-dial mechanism for self-administration.
Common use case
Patients or caregivers who prefer pen delivery for convenience and dosing precision.
Dosage note
Follow pen-specific instructions for priming and dialing dose. Dispose of used pens per local sharps regulations.
Somatropin biosimilars
Biosimilar somatropin products from other manufacturers approved in various regulatory jurisdictions with comparable amino-acid sequence and indications.
Common use case
Patients where biosimilars are approved and covered; regulatory approval ensures comparable efficacy and safety standards.
Dosage note
Dosing principles mirror the reference product but follow the specific biosimilar's labeling. Substitution policies vary by region and payer.
Higher pediatric dosing regimens (e.g., Turner syndrome)
Selected pediatric indications such as Turner syndrome use higher weekly doses to maximize growth response under specialist supervision.
Common use case
Pediatric indications with evidence supporting higher doses, managed by a pediatric endocrinologist.
Dosage note
Doses up to approximately 0.33 mg/kg/week may be used; growth velocity, IGF-1, and adverse effects require close monitoring.
Dosage and best practices
Dosage principles
- Pediatric growth hormone deficiency: typical starting dose 0.16–0.24 mg/kg/week subcutaneously, divided into daily injections (approximately 0.022–0.034 mg/kg/day); adjusted by indication, growth response, and IGF-1 levels per the Genotropin prescribing information.
- Turner syndrome and selected short-stature indications: higher pediatric doses are often used (up to approximately 0.33 mg/kg/week) under specialist guidance; dose is individualized by diagnosis and monitoring.
- Adult GH deficiency: typical starting dose 0.2–0.4 mg/day subcutaneously at bedtime for younger adults; lower starting doses (0.1 mg/day) for older patients or those with diabetes. Titrate every 1–2 months by symptoms, side effects, and IGF-1 within the age-adjusted reference range; usual maintenance does not exceed approximately 1.0 mg/day.
- For all patients: use the lowest effective dose that achieves clinical goals and maintains IGF-1 within the appropriate age-adjusted range. Monitor glucose, lipids, IGF-1, and adverse effects at regular intervals.
Best practices
- Treatment must be prescribed and monitored by an endocrinologist or clinician experienced with GH therapy. Baseline evaluation should include pituitary imaging (when indicated), fasting glucose, and assessment for active malignancy or contraindications.
- Administer subcutaneously, typically at bedtime to align with physiologic nocturnal GH secretion. Rotate injection sites and follow manufacturer instructions for reconstitution or pen use.
- Monitor growth velocity in children and body composition in adults; track IGF-1, fasting glucose/HbA1c, thyroid function, and signs of fluid retention or intracranial hypertension. Adjust dose based on objective findings.
Literature and references
Genotropin (somatropin) prescribing information
Pfizer / DailyMed • 2020
Manufacturer prescribing information describing approved indications, weight-based and fixed dosing regimens for pediatric and adult GH deficiency, contraindications, and safety monitoring requirements.
Genotropin — European Public Assessment Report (EPAR)
European Medicines Agency • 2017
EMA regulatory assessment summarizing clinical data, approved indications, and post-marketing surveillance considerations for Genotropin in Europe.
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Journal of Clinical Endocrinology & Metabolism • 2011
Endocrine Society guideline covering diagnostic criteria (provocative testing), dosing principles, IGF-1 titration targets, and monitoring recommendations for adult GH deficiency and replacement therapy.
Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society
The Journal of clinical endocrinology and metabolism • 2000
Common questions
Is Genotropin safe for anti-aging or athletic performance?
No. GH for anti-aging or performance enhancement is not supported by clinical evidence, is not approved for these purposes, and carries real risks including fluid retention, glucose intolerance, and potential long-term harms. Use outside of approved medical indications should be avoided.
How long before results are noticeable?
In children, increased growth velocity is typically evident within 3–6 months. Final height benefit depends on age at initiation and total treatment duration. In adults, changes in body composition and energy may emerge over several months. Objective monitoring — height in children, IGF-1, body composition, and labs in adults — should guide expectations rather than subjective impression alone.
Does GH treatment increase cancer risk?
Registry data to date do not show a clearly elevated rate of de-novo malignancy in patients treated for approved indications. However, IGF-1 promotes cell proliferation, and GH is contraindicated in active malignancy. Cancer survivors considering GH therapy require individualized risk-benefit assessment. Monitoring continues through long-term registries.
Can Genotropin be taken orally or as a patch?
No. Somatropin is a large protein that is broken down in the digestive tract before it can reach systemic circulation. It must be administered by subcutaneous injection. No oral or transdermal formulation provides clinically meaningful delivery.